Skip to content
10-Q

Quarterly Report

BioCrude Technologies USA, Inc.

0001731122-23-002066

← back to feed
Filed
Nov 13, 2023 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2023 · Nov 13, 2023 50.8M sh
Short Term Debt Q3 2023 · Sep 30, 2023 $128.48K
Short Term Debt Q3 2023 · Dec 31, 2022 $126K
Stockholders Equity Q3 2023 · Sep 30, 2023 −$196.88K
Stockholders Equity Q3 2023 · Dec 31, 2022 −$147K
Current Liabilities Q3 2023 · Sep 30, 2023 $217.31K
Current Liabilities Q3 2023 · Dec 31, 2022 $173.07K
Total Liabilities Q3 2023 · Sep 30, 2023 $217.31K
Total Liabilities Q3 2023 · Dec 31, 2022 $173.01K
Current Assets Q3 2023 · Sep 30, 2023 $38
Current Assets Q3 2023 · Dec 31, 2022 $4.79K
Total Assets Q3 2023 · Sep 30, 2023 $17.06K
Total Assets Q3 2023 · Dec 31, 2022 $22.68K
Shares Diluted Q3 2023 · Sep 30, 2022 50.72M sh
Shares Diluted Q3 2023 · Sep 30, 2022 50.72M sh
Capex Q3 2023 · Sep 30, 2022 $0
Operating Cash Flow Q3 2023 · Sep 30, 2022 −$145.03K
Eps Diluted Q3 2023 · Sep 30, 2022 $0.00
Eps Diluted Q3 2023 · Sep 30, 2022 $0.00
Eps Basic Q3 2023 · Sep 30, 2022 $0.00
Eps Basic Q3 2023 · Sep 30, 2022 $0.00
Sga Expense Q3 2023 · Sep 30, 2022 $88.3K
Sga Expense Q3 2023 · Sep 30, 2022 $155.87K
Net Income Q3 2023 · Sep 30, 2022 −$89.26K
Net Income Q3 2023 · Jun 30, 2022 −$15.51K
Net Income Q3 2023 · Mar 31, 2022 −$54.04K
Operating Income Q3 2023 · Sep 30, 2022 −$88.3K
Operating Income restated Q3 2023 · Sep 30, 2022 −$155.87K